Sequenta Raises $13M for Development of Immune Repertoire Sequencing-Based Diagnostics | GenomeWeb

This article has been updated from a version posted Dec. 8 to include comments from a company director.

Sequenta, a molecular diagnostics company focused on developing an assay based on immune repertoire sequencing, has raised $13 million in a Series B financing round. The financing was led by Index Ventures, Mohr Davidow Ventures, and several individual investors.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.